Regeneron and Sanofi Announce FDA Priority Review for Dupixent® as Potential First Targeted Treatment for Bullous Pemphigoid
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1194842257-aea6c7d2d75f42c6a081581cd0c01fd1.jpg "Breaking Down the Binomial Model to Value an Option")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1485541136-ebeb906243274021953080d4e4f8e572.jpg "The Iron Condor: How This Options Trading Strategy Make Make (or Lose) Money")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1681118613-f3652ffa5f3042ee8d4bd5c723050a5e.jpg "Should I Invest or Pay off My Mortgage?")